Daiichi Sankyo's Majority Stake In Ranbaxy Will Increase Production Capacity In India, Expand Global Footprint In Developing Markets – Japanese Analysts
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo will make a foray into the generics business with its Ranbaxy acquisition, and will shift much of its domestic production to Ranbaxy to save costs, analysts in Japan said. However, the Japanese company will not sell its brand drugs through Ranbaxy's distribution channels, nor will the two companies start a joint generics business in Japan, they speculated